Assets

Accelerating Discovery through Co-Development

R&D Partnerships

GenomeMiner can work with you for co-development of an asset in various partnership structures.

  • Microbe activity screening
  • Secondary Metabolite Analysis
  • Genetic engineering/small scale culture
  • DNA/RNA sequencing and analysis on the GenomeMiner platform
  • Apatamer screening/biosensor development
Partners:
Contact Us ►

Our Asset Pipeline

We have multiple assets in development, the most mature being our biopesticide candidates.

Commerical Assets

Asset

Initial Lead Candidate

Feasibility Study

Licensing

Nematode Control

Passed 2nd stage feasibility study test with partner company

Antifungal Biopesticide

Stage 1 feasibility study with partner company

Proprietary Polyketide BGCs

Multiple Actinomyces collected. Analysis in progress. In discussion with partner company

Probiotic Animal Feed

Candidates obtained. Seeking agriculture partners in Japan & Indonesia

Clinical Assets

Asset

Preclinical

Clinical 1

Clinical 2

Clinical 3

MRSA Antibiotic

Novel active compounds found from wet-lab screen.

On-Target

clinical product / genetic engineering asset

Our fusion protein shows efficacy for targeted DNA insertion in e-coli. Patent filed (Jan, 2022)

Applications

Medicine

Identify novel Biosynthetic Gene Clusters and enzyme for therapeutic compound production.

Agriculture

Identify microbes that have the appropriate profile for  environment and human friendly alternatives to conventional agricultural chemicals.

More...

Replace industrial methods of chemical production by using microbes to achieve sustainability goals.